Skip to main content
All Posts By

laurabbook@gmail.com

MEDPAGE TODAY
ResearchTreatments

Revisiting Chemo in EGFR-Mutant NSCLC

*December 2019* Adding chemotherapy to a targeted agent doubled progression-free survival (PFS) for patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), according to two randomized trials. A phase III trial from India showed that median PFS increased from 8 months with the EGFR inhibitor gefitinib (Iressa) to 16 months with gefitinib…
laurabbook@gmail.com
January 18, 2020
dana farber logo
FundingResearch

Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers

*January 2020* Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer. The Chen-Huang Center is being established with a $5 million gift from Winston Chen,…
laurabbook@gmail.com
January 18, 2020
EGFR Resisters logo
AdvocacyCoping With CancerResearch

Project PRIORITY: Why it matters to the EGFR-positive lung cancer community

*December 2019* Project PRIORITY (Patient Reported Initiative On Resistance, Incidence, Treatment studY), is a collaboration between LUNGevity Foundation and the EGFR Resisters—a grassroots, patient-driven community dedicated exclusively to changing EGFR-positive lung cancer into a manageable chronic disease. Goal of Project PRIORITY To understand unmet needs of the EGFR-positive lung cancer…
laurabbook@gmail.com
December 20, 2019
EGFR Resisters logo
ResearchTreatments

New Clinical Trials

*November 2019* Phase II progression on any TKI with a new 3rd generation TKI, lazertinib. Location: Montefiore/Einstein in NYC. More information. The JNJ-372 (or JJNJ-61186372) was recently updated with the addition of Lazertinib as one of its arms to be given in combo with JNJ-372 drug or separately and is/or…
laurabbook@gmail.com
November 8, 2019
Onc Live
ResearchTreatments

Overcoming Targeted Therapy Resistance in NSCLC

*October 2019*  by Caroline Seymour for OncLive Insight into the natural history of EGFR-, ALK-, and ROS1-positive non–small cell lung cancer (NSCLC) has led to the development of novel targeted treatments in the frontline setting as well as expanding options for those with progressive disease, explained Timothy F. Burns, MD,…
laurabbook@gmail.com
November 8, 2019